Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

Clemence Marcault, MD, Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-136177

Published: 2020

Journal Articles

Ruxolitinib Treatment Is Associated with Increased Incidence of Infections and Higher Risk of HSV/Vzv Recurrence in Patients with Myeloproliferative Neoplasm (MPN) Related Myelofibrosis (MF)

Nicolas Gauthier, MD, Juliette Soret-Dulphy, MD, Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Clemence Marcault, MD, Nathalie Parquet, MD, Jean-Marc Zini, Delphine Rea, MDPhD, Emmanuel Raffoux, MD, Bruno Cassinat, PharmD, PhD, Stephane Giraudier, MD PhD, Jean-Jacques Kiladjian, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-141260

Published: 2020

Journal Articles

Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission

Rafael Daltro De Oliveira, MD, Juliette Soret-Dulphy, MD, Lin-Pierre Zhao, MD, Clemence Marcault, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Nathalie Parquet, MD, Emmanuel Raffoux, MD, William Vainchenker, Christine Chomienne, MD PhD, Bruno Cassinat, PharmD, PhD, Lina Benajiba, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-141223

Published: 2020

Journal Articles

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Clemence Marcault, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, MD, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD PhD, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141296

Published: 2020

Journal Articles

JMML Fetal Identity Results Either from Retention of a Physiologic Signature or Aberrant Activation of Master Oncofetal Regulators

Marion Strullu, MD, Aurélie Caye-Eude, PharmD, PhD, Loïc Maillard, PhD, Chloé Arfeuille, MD, Elodie Lainey, PharmD, PhD, Florian Piques, MD, Odile Fenneteau, PharmD, Bruno Cassinat, PharmD, PhD, Fabien Guimiot, PhD, Jean-Hugues Dalle, MD PhD, André Baruchel, Christine Chomienne, MD PhD, Dominique Bonnet, PhD, Michele Souyri, PhD, Hélène Cavé, PharmD, PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-136367

Published: 2020

Journal Articles

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Blood (2019) 134 (Supplement_1): 4196.

https://doi.org/10.1182/blood-2019-127903

Published: 2019

Journal Articles

Current Treatments Do Not Improve the Prognosis of Patients with Atypical CML and Unclassified MDS/MPN. a Joint Report from Fi-LMC, FIM, Gfch and GFM

Vaidie Julien, MD, Delphine Rea, MD, Sylvain Thepot, MD, Le Pluart Bruno, MD, Nathalie Gachard, PhD, Stéphanie Struski, MD, Lydia Roy, MD, Cecile Bally, MD, Jo Caers, MD PhD, Franck E Nicolini, MD PhD, Bruno Cassinat, PharmD, PhD, Eric Lippert, MD PhD, Laurence Legros, MD PhD, Raphael Itzykson, MD PhD

Blood (2019) 134 (Supplement_1): 2954.

https://doi.org/10.1182/blood-2019-127254

Published: 2019

Journal Articles

Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses

Pierre-Edouard Debureaux, Bruno Cassinat, PharmD, PhD, Juliette Soret-Dulphy, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Pierre-Emmanuel Rautou, MD PhD, Aurelie Plessier, Dominique Valla, Stephane Giraudier, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2019) 134 (Supplement_1): 836.

https://doi.org/10.1182/blood-2019-123775

Published: 2019

Journal Articles

Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin

Bridget Marcellino, MD PhD, Bruno Cassinat, PharmD, PhD, Noushin Farnoud, PhD, Min Lu, PhD, Emmanuelle Verger, PhD, Erin McGovern, BA, Minal A Patel, MPH, Heidi E. Kosiorek, MS, Meenakshi Mehrotra, PhD, Jane Houldsworth, PhD, Amylou C. Dueck, PhD, Michael Rossi, PhD, Jean-Jacques Kiladjian, MD PhD, Raajit K. Rampal, MD PhD, John Mascarenhas, MD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 838.

https://doi.org/10.1182/blood-2019-128342

Published: 2019

Journal Articles

Differential Impact of Interferon Alpha on JAK2 V617F and Calr Mutated Hematopoietic Stem and Progenitor Cells in Classical MPN

Matthieu Mosca, PhDstudent, Lamia Lamrani, PhD, Christophe Marzac, MD, Amandine Tisserand, Valérie Edmond, PhD, Tracy Dagher, PhDstudent, Mira El-Khoury, PhD, Caroline Marty, PhD, Hugo Campario, PharmD, Nicole Casadevall, MD, Eric Solary, MD PhD, Hana Raslova, PhD, Bruno Cassinat, PharmD, PhD, Stefan N Constantinescu, MD, Jean-Jacques Kiladjian, MD PhD, Francois Girodon, MD PhD, Jean-Luc Villeval, PhD, William Vainchenker, MD PhD, Isabelle Plo, PhD

Blood (2018) 132 (Supplement 1): 4333.

https://doi.org/10.1182/blood-2018-99-114744

Published: 2018

Journal Articles

A Fast and Accurate Cartridge-Based RT-qPCR Assay to Quantify PML-Rara mRNA Fusion Transcripts Near the Point of Care

Natalie Chi-hwa Wu, PhD, Monisha Malek, B.S., Ken Ho, B.S, Julia Chen, PhD, Anvita Komarla, B.S., Victor Chu, PhD, Huilin Wei, MD PhD, Gwo-Jen Day, PhD, Jean-Michel Cayuela, PhD, Christophe Ferrand, PhD, Bruno Cassinat, PharmD, PhD

Blood (2018) 132 (Supplement 1): 1481.

https://doi.org/10.1182/blood-2018-99-110111

Published: 2018

Journal Articles

Comprehensive Clinical-Molecular Transplant Risk Model for Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation

Nico Gagelmann, Markus Ditschkowski, Rashit Bogdanov, Marie Robin, MD PhD, Bruno Cassinat, PharmD, PhD, Michael Heuser, MD, Rabia Shahswar, Felicitas Thol, MD, Dietrich W. Beelen, Anita Badbaran, Nicolaus Kroeger

Blood (2018) 132 (Supplement 1): 689.

https://doi.org/10.1182/blood-2018-99-114636

Published: 2018

Journal Articles

Specific and Synergistic Targeting of JAK2V617F Cells By Interferon Alpha and Arsenic

Nabih Maslah1, PharmD, Tracy Dagher, PhDstudent, Valérie Edmond, PhD, Bruno Cassinat, PharmD, PhD, Valérie Lallemand-Breitenbach, PhD, Emmanuelle Verger, PhD, Isabelle Plo, PhD, Jean-Jacques Kiladjian, MD PhD, Jean-Luc Villeval, PhD, Hugues de Thé, MD PhD

Blood (2018) 132 (Supplement 1): 52.

https://doi.org/10.1182/blood-2018-99-112518

Published: 2018

Journal Articles

BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to Treatment

Rose Ann Padua, PhD, Laure Sarda-Mantel, MD PhD, Mathieu Chiquet, BSc, Claire Kappel, BSc, Patricia Krief, PhD, Niclas Setterblad, PhD, Fortune Hontonnou, BSc, Benoit Hosten, PhD, Nicolas Vignal, BSc, Fabien Zassadowski, PhD, Bruno Cassinat, PharmD, PhD, Panhong Gou, BSc, Stephane Giraudier, MD PhD, Marina Y. Konopleva, MD PhD, Michael Andreeff, MD PhD, Marika PLA, PhD, Lionel Ades, MD PhD, Pierre Fenaux, MD PhD, Christine Chomienne, MD PhD

Blood (2018) 132 (Supplement 1): 5497.

https://doi.org/10.1182/blood-2018-99-114212

Published: 2018

Journal Articles

Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis

Jean-Jacques Kiladjian, MD PhD, Juliette Soret-Dulphy, MD, Matthieu Resche-Rigon, MD PhD, Francoise Boyer-Perrard, MD, Fiorenza Barraco, MD, Valérie Rolland-Neyret, Claude Capron, Sylvie Chevret, MD PhD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD

Blood (2018) 132 (Supplement 1): 581.

https://doi.org/10.1182/blood-2018-99-110785

Published: 2018

Journal Articles

JAK2V617F - Positive Endothelial Cells Display Pro-Thrombotic Characteristics

Anna Guadall, PhD, Elodie Lesteven, PharmD, PhD, Gil Letort, Sarah Awan Toor, Doriane Pognant, Megane Brusson, Emmanuelle Verger, PhD, Jerome Larghero, PharmD, PhD, Valerie Vanneaux, PharmD, PhD, Christine Chomienne, MD PhD, Wassim El Nemer, PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2016) 128 (22): 4273.

https://doi.org/10.1182/blood.V128.22.4273.4273

Published: 2016

Journal Articles

Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia

Cecile Bally, Jacqueline Lehmann-Che, Bruno Cassinat, PharmD, PhD, Lionel Ades, MD PhD, Eric Letouze, Pierre Hirsch, Marie-Joelle Mozziconacci, Sophie Raynaud, MD, Eric Delabesse, PharmD, PhD, Madalina Uzunov, MD, Mathilde Hunault, MD PhD, Eric Lippert, PhD, Hélène Lapillonne, MD PhD, Christophe Ferrand, PhD, Carine Gervais, MD, Nathalie Gachard, PhD, Agnès Guerci, MD PhD, Pierre Fenaux, MD PhD, Hugues de The, MD PhD

Blood (2016) 128 (22): 2892.

https://doi.org/10.1182/blood.V128.22.2892.2892

Published: 2016

Journal Articles

Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation

Juliette Soret, MD, Bruno Cassinat, PharmD, PhD, Sylvie Chevret, MD PhD, Christine Dosquet, MD PhD, Stephane Giraudier, MD PhD, Emmanuelle Verger, PhD, Nabih Maslah, PhD, Nathalie Parquet, MD, Christine Chomienne, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2016) 128 (22): 3106.

https://doi.org/10.1182/blood.V128.22.3106.3106

Published: 2016

Journal Articles

Pro-Coagulant and Pro-Inflammatory Effect of Interferon Alpha in Myeloproliferative Neoplasms

Nadine Ajzenberg, MD PhD, Dorothee Faille, PharmD, PhD, Lamia Lamrani, PhD, Stéphane Loyau, Marie-Geneviève Huisse, MD PhD, Nicolas Dumontier, PharmD, Martine Jandrot-Perrus, MD PhD, Sawsaneh Alkhaier, Bruno Cassinat, PharmD, PhD, Christine Chomienne, MD PhD, Christine Dosquet, MD PhD

Blood (2016) 128 (22): 1941.

https://doi.org/10.1182/blood.V128.22.1941.1941

Published: 2016

Journal Articles

Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases

Philippe Attias, Aline Renneville, MD, Xavier Thomas, MD PhD, Cecile Bally, Sandrine Hayette, Hassan Farhat, MD, Virginie Eclache, MD, Alice Marceau, Bruno Cassinat, PharmD, PhD, Jean Feuillard, MD PhD Pr, Christine Terré, PharmD, PhD, Eric Delabesse, PharmD, PhD, Sophie Park, MD PhD, Julie Lejeune, Sylvie Chevret, MD PhD, Lionel Ades, MD PhD, Claude Preudhomme, MD PhD, Pierre Fenaux, MD PhD

Blood (2016) 128 (22): 2861.

https://doi.org/10.1182/blood.V128.22.2861.2861

Published: 2016

NARROW

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

Ruxolitinib Treatment Is Associated with Increased Incidence of Infections and Higher Risk of HSV/Vzv Recurrence in Patients with Myeloproliferative Neoplasm (MPN) Related Myelofibrosis (MF)

Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

JMML Fetal Identity Results Either from Retention of a Physiologic Signature or Aberrant Activation of Master Oncofetal Regulators

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Current Treatments Do Not Improve the Prognosis of Patients with Atypical CML and Unclassified MDS/MPN. a Joint Report from Fi-LMC, FIM, Gfch and GFM

Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses

Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin

Differential Impact of Interferon Alpha on JAK2 V617F and Calr Mutated Hematopoietic Stem and Progenitor Cells in Classical MPN

A Fast and Accurate Cartridge-Based RT-qPCR Assay to Quantify PML-Rara mRNA Fusion Transcripts Near the Point of Care

Comprehensive Clinical-Molecular Transplant Risk Model for Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation

Specific and Synergistic Targeting of JAK2V617F Cells By Interferon Alpha and Arsenic

BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to Treatment

Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis

JAK2V617F - Positive Endothelial Cells Display Pro-Thrombotic Characteristics

Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia

Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation

Pro-Coagulant and Pro-Inflammatory Effect of Interferon Alpha in Myeloproliferative Neoplasms

Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only